BARTALUCCI, NICCOLO'
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.301
EU - Europa 3.004
AS - Asia 1.951
SA - Sud America 234
Continente sconosciuto - Info sul continente non disponibili 89
AF - Africa 48
OC - Oceania 22
Totale 9.649
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.212
RU - Federazione Russa 920
IT - Italia 644
PL - Polonia 632
SG - Singapore 566
CN - Cina 534
HK - Hong Kong 272
VN - Vietnam 186
IE - Irlanda 183
BR - Brasile 179
KR - Corea 160
SE - Svezia 151
DE - Germania 99
FR - Francia 87
FI - Finlandia 76
IN - India 72
GB - Regno Unito 70
CH - Svizzera 58
CA - Canada 55
JO - Giordania 26
BD - Bangladesh 24
AU - Australia 22
ID - Indonesia 21
JP - Giappone 19
AR - Argentina 18
NL - Olanda 18
ES - Italia 16
CI - Costa d'Avorio 13
MX - Messico 13
NG - Nigeria 13
UA - Ucraina 11
BE - Belgio 10
TR - Turchia 10
IQ - Iraq 8
PH - Filippine 8
PY - Paraguay 8
AT - Austria 7
AE - Emirati Arabi Uniti 6
CL - Cile 6
CO - Colombia 6
PK - Pakistan 6
SA - Arabia Saudita 6
UZ - Uzbekistan 6
VE - Venezuela 6
EC - Ecuador 5
KZ - Kazakistan 5
JM - Giamaica 4
MY - Malesia 4
TT - Trinidad e Tobago 4
BJ - Benin 3
CR - Costa Rica 3
DZ - Algeria 3
GR - Grecia 3
HN - Honduras 3
MA - Marocco 3
ZA - Sudafrica 3
AZ - Azerbaigian 2
BO - Bolivia 2
CG - Congo 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
HU - Ungheria 2
KE - Kenya 2
KH - Cambogia 2
LB - Libano 2
LT - Lituania 2
LV - Lettonia 2
PE - Perù 2
PR - Porto Rico 2
TN - Tunisia 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AG - Antigua e Barbuda 1
AL - Albania 1
BB - Barbados 1
BY - Bielorussia 1
CU - Cuba 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
EE - Estonia 1
GA - Gabon 1
HR - Croazia 1
KW - Kuwait 1
LK - Sri Lanka 1
MT - Malta 1
MU - Mauritius 1
NI - Nicaragua 1
NO - Norvegia 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
TG - Togo 1
TH - Thailandia 1
TW - Taiwan 1
YT - Mayotte 1
Totale 9.563
Salva come PNG Salva come JPEG
Città #
Santa Clara 867
Warsaw 629
Ashburn 568
Singapore 405
Fairfield 289
Hong Kong 230
San Jose 196
Dublin 183
Chandler 163
Seoul 159
Woodbridge 142
Seattle 140
Beijing 123
Houston 115
Hefei 108
Cambridge 107
Florence 99
Milan 97
Wilmington 97
Dallas 96
Ann Arbor 88
Council Bluffs 78
Los Angeles 68
Buffalo 66
Ho Chi Minh City 62
Altamura 59
Lawrence 59
Bern 58
Rome 46
The Dalles 46
Hanoi 45
Lauterbourg 45
New York 45
Princeton 43
Moscow 42
Munich 39
Mumbai 37
Boston 32
Helsinki 29
Kent 27
Paris 24
Shanghai 24
Bremen 23
Turku 22
Melbourne 20
Tokyo 19
Medford 18
Phoenix 18
Clifton 17
São Paulo 17
Boardman 16
Chicago 16
Jakarta 16
London 16
Orem 16
Denver 15
San Diego 15
Turin 15
Abidjan 13
Abuja 13
Frankfurt am Main 13
Montreal 13
Brooklyn 12
Dong Ket 12
Naples 12
Toronto 12
Da Nang 11
Jacksonville 11
Brussels 10
Falls Church 10
Redondo Beach 10
Elk Grove Village 9
Lappeenranta 9
St Louis 9
Amsterdam 8
Bologna 8
Chennai 8
Indianapolis 8
Palermo 8
Tianjin 8
West Jordan 8
Figino 7
Mexico City 7
Cagliari 6
Guangzhou 6
Manchester 6
North Bergen 6
Norwalk 6
Pian di Scò 6
Porto Alegre 6
Pune 6
Tashkent 6
Waltham 6
Atlanta 5
Bengaluru 5
Haiphong 5
Hillsboro 5
Rignano sull'Arno 5
San Francisco 5
Venice 5
Totale 6.498
Salva come PNG Salva come JPEG
Nome #
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. 350
Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial 346
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. 324
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera. 288
Differentiation of crescent-forming kidney progenitor cells into podocytes attenuates severe glomerulonephritis in mice 273
Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/ CIP2A axis 268
Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants 264
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) 233
Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation 230
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value 223
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis 210
THIRD GENERATION SEQUENCING OF NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA: IMPLICATIONS FOR PROGNOSIS 205
Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. 203
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. 200
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea 199
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 197
Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data 193
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients 193
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis 187
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features 179
Long Reads, Short Time: Feasibility of Prenatal Sample Karyotyping by Nanopore Genome Sequencing 177
Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis 176
Studio della via di segnalazione Akt/mTOR nelle Neoplasie Mieloproliferative Croniche 171
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis 171
Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis 171
Peripheral nerve resident macrophages and schwann cells mediate cancer-induced pain A C 170
Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs 169
Novel insights into myelofibrosis pathophysiology and treatment 168
Preclinical models for drug selection in myeloproliferative neoplasms. 166
Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model 164
The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis 162
Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2 160
Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms. 158
Familial dominant epilepsy and mild pachgyria associated with a constitutional LIS1 mutation 156
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 156
JAK PI3K/mTOR COMBINATION THERAPY 154
Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells 152
Resolving complex structural variants via nanopore sequencing 143
No role for CXCL12-G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia. 143
NANOR: A user-friendly R package to analyze and compare nanopore sequencing data 142
Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms 140
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates 139
Rationale for combination therapies in myelofibrosis 139
A blood drop through the pore: nanopore sequencing in hematology 136
Philadelphia-negative myeloproliferative neoplasms: From origins to new perspectives 134
Targeting the PI3K pathway in myeloproliferative neoplasms 133
A novel approach for highly sensitive and rapid identification of HMGA2 submicroscopic deletions in myeloproliferative neoplasms 120
Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms. 116
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. 113
Chromosome 9p trisomy increases stem cells clonogenic potential and fosters T-cell exhaustion in JAK2-mutant myeloproliferative neoplasms 112
Polycythemia vera: the current status of preclinical models and therapeutic targets 99
CD44 Participates to Extramedullary Haematopoiesis Onset by Mediating the Interplay Between Monocytes and Haematopoietic Stem Cells in Myelofibrosis 77
Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis 60
Clinical Experience With Venetoclax-Based Combinations for Relapsed/Refractory or MRD-Positive NPM1-Mutated Acute Myeloid Leukemia. 50
Correction: A novel approach for highly sensitive and rapid identification of HMGA2 submicroscopic deletions in myeloproliferative neoplasms 46
Genomic structural variations contribute to inform prognosis in patients with cytogenetically normal acute myeloid leukemia 23
A Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative Neoplasm 18
Totale 9.649
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.755
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.755
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022286 0 0 40 7 9 18 5 27 24 15 54 87
2022/2023850 70 177 48 59 44 137 109 51 64 6 18 67
2023/2024408 17 34 55 20 43 54 6 81 12 30 36 20
2024/20252.612 77 247 159 415 685 375 80 130 111 79 127 127
2025/20263.139 353 429 300 253 336 112 373 145 204 201 107 326
2026/2027437 207 92 138 0 0 0 0 0 0 0 0 0
Totale 9.649